BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26464698)

  • 1. Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.
    Tajima S; Fukayama M
    Int J Clin Exp Pathol; 2015; 8(8):9422-7. PubMed ID: 26464698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the "nonphosphaturic" variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization.
    Sent-Doux KN; Mackinnon C; Lee JC; Folpe AL; Habeeb O
    Hum Pathol; 2018 Oct; 80():94-98. PubMed ID: 29514106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour.
    Lee JC; Jeng YM; Su SY; Wu CT; Tsai KS; Lee CH; Lin CY; Carter JM; Huang JW; Chen SH; Shih SR; Mariño-Enríquez A; Chen CC; Folpe AL; Chang YL; Liang CW
    J Pathol; 2015 Mar; 235(4):539-45. PubMed ID: 25319834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From epistaxis to bone pain-report of two cases illustrating the clinicopathological spectrum of phosphaturic mesenchymal tumour with fibroblast growth factor receptor 1 immunohistochemical and cytogenetic analyses.
    Mok Y; Lee JC; Lum JH; Petersson F
    Histopathology; 2016 May; 68(6):925-30. PubMed ID: 26407099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.
    Lee JC; Su SY; Changou CA; Yang RS; Tsai KS; Collins MT; Orwoll ES; Lin CY; Chen SH; Shih SR; Lee CH; Oda Y; Billings SD; Li CF; Nielsen GP; Konishi E; Petersson F; Carpenter TO; Sittampalam K; Huang HY; Folpe AL
    Mod Pathol; 2016 Nov; 29(11):1335-1346. PubMed ID: 27443518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent overexpression of klotho in fusion-negative phosphaturic mesenchymal tumors with tumorigenic implications.
    Lee CH; Su SY; Sittampalam K; Chen PC; Petersson F; Kao YC; Carpenter TO; Hsieh TH; Konishi E; Tsai JW; Billings SD; Folpe AL; Lee JC
    Mod Pathol; 2020 May; 33(5):858-870. PubMed ID: 31792355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant.
    Shiba E; Matsuyama A; Shibuya R; Yabuki K; Harada H; Nakamoto M; Kasai T; Hisaoka M
    Diagn Pathol; 2016 Mar; 11():26. PubMed ID: 26956379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
    Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
    Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia.
    Bahrami A; Weiss SW; Montgomery E; Horvai AE; Jin L; Inwards CY; Folpe AL
    Am J Surg Pathol; 2009 Sep; 33(9):1348-54. PubMed ID: 19609206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant.
    Yamada Y; Kinoshita I; Kenichi K; Yamamoto H; Iwasaki T; Otsuka H; Yoshimoto M; Ishihara S; Toda Y; Kuma Y; Setsu N; Koga Y; Honda Y; Inoue T; Yanai H; Yamashita K; Ito I; Takahashi M; Ohga S; Furue M; Nakashima Y; Oda Y
    Histopathology; 2018 Feb; 72(3):460-471. PubMed ID: 28858396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis.
    Uchihashi K; Nishijima-Matsunobu A; Matsuyama A; Yamasaki F; Tanabe T; Uemura T; Aragane N; Yakushiji M; Yamamoto M; Aoki S; Toda S
    Hum Pathol; 2013 Nov; 44(11):2614-8. PubMed ID: 23954138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
    BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis.
    Wasserman JK; Purgina B; Lai CK; Gravel D; Mahaffey A; Bell D; Chiosea SI
    Head Neck Pathol; 2016 Sep; 10(3):279-85. PubMed ID: 26759148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors.
    Carter JM; Caron BL; Dogan A; Folpe AL
    Am J Surg Pathol; 2015 Jan; 39(1):75-83. PubMed ID: 25025444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphaturic Mesenchymal Tumors: Clinicopathologic, Immunohistochemical and Molecular Analysis of 22 Cases Expanding their Morphologic and Immunophenotypic Spectrum.
    Agaimy A; Michal M; Chiosea S; Petersson F; Hadravsky L; Kristiansen G; Horch RE; Schmolders J; Hartmann A; Haller F; Michal M
    Am J Surg Pathol; 2017 Oct; 41(10):1371-1380. PubMed ID: 28614212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphaturic mesenchymal tumors: A review and update.
    Folpe AL
    Semin Diagn Pathol; 2019 Jul; 36(4):260-268. PubMed ID: 31301876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
    Boland JM; Tebben PJ; Folpe AL
    J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome.
    Berglund JA; Gafni RI; Wodajo F; Cowen EW; El-Maouche D; Chang R; Chen CC; Guthrie LC; Molinolo AA; Collins MT
    Osteoporos Int; 2018 Apr; 29(4):993-997. PubMed ID: 29380000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.
    Tajima S; Fukayama M
    Int J Clin Exp Pathol; 2015; 8(8):9390-6. PubMed ID: 26464693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.
    Ghorbani-Aghbolaghi A; Darrow MA; Wang T
    Autops Case Rep; 2017; 7(3):32-37. PubMed ID: 29043208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.